Literature DB >> 7779721

Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma.

J W Mulder1, I O Baas, M M Polak, S N Goodman, G J Offerhaus.   

Abstract

Mutation of the p53 gene is reported to be of prognostic importance in colorectal carcinomas. Immunohistochemical staining of the accumulated p53 gene product may be a simple alternative for p53 mutation analysis. Previous studies addressing the prognostic importance of p53 expression, however, yielded contradictory results. Therefore, we evaluated the importance of p53 expression as a marker for long-term prognosis in a well-characterised study population of 109 colorectal carcinomas. After antigen retrieval with target unmasking fluid (TUF), immunostaining of p53 was performed with both monoclonal antibody DO7 and polyclonal antibody CM1. Objective quantification of the p53 signal was assessed by a computerised image analyser. p53 expression was higher in non-mucinous tumours than in mucinous tumours (p53 labelling index = 30% and 17% respectively, P = 0.05), and in metastatic tumours compared with non-metastatic tumours (p53 labelling index = 37% and 22% respectively, P = 0.05). Other histopathological features were not related to p53 expression. In multivariate analysis, Dukes' stage (P = 0.02) and histological grade (P = 0.05) stood out as independent markers for prognosis. p53 expression was not an independent marker for prognosis. At present, p53 expression is not a useful marker for long-term prognosis. Further insight into the relationship between p53 mutations and p53 expression is needed to elucidate more precisely the clinical relevance of p53 alterations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7779721      PMCID: PMC2033814          DOI: 10.1038/bjc.1995.243

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  43 in total

1.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

2.  Histopathology of colorectal carcinomas and adenomas in cancer family syndrome.

Authors:  J P Mecklin; P Sipponen; H J Järvinen
Journal:  Dis Colon Rectum       Date:  1986-12       Impact factor: 4.585

3.  Cancer of the colon: the influence of the no-touch isolation technic on survival rates.

Authors:  R B Turnbull; K Kyle; F R Watson; J Spratt
Journal:  Ann Surg       Date:  1967-09       Impact factor: 12.969

4.  Significance of venous and lymphatic invasion in malignant polyps of the colon and rectum.

Authors:  S Muller; I M Chesner; M J Egan; D C Rowlands; M J Collard; E T Swarbrick; J Newman
Journal:  Gut       Date:  1989-10       Impact factor: 23.059

5.  p53 mutations in colorectal cancer.

Authors:  N R Rodrigues; A Rowan; M E Smith; I B Kerr; W F Bodmer; J V Gannon; D P Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

6.  Relationship among p53, stage, and prognosis of large bowel cancer.

Authors:  S D Nathanson; M D Linden; P Tender; R J Zarbo; G Jacobsen; L T Nelson
Journal:  Dis Colon Rectum       Date:  1994-06       Impact factor: 4.585

7.  Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator.

Authors:  D M Graham; H D Appelman
Journal:  Mod Pathol       Date:  1990-05       Impact factor: 7.842

8.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

9.  Lymphocytic infiltration and survival in rectal cancer.

Authors:  J R Jass
Journal:  J Clin Pathol       Date:  1986-06       Impact factor: 3.411

10.  Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected].

Authors:  S E Kern; E R Fearon; K W Tersmette; J P Enterline; M Leppert; Y Nakamura; R White; B Vogelstein; S R Hamilton
Journal:  JAMA       Date:  1989-06-02       Impact factor: 56.272

View more
  11 in total

Review 1.  Molecular markers to individualize adjuvant therapy for colon cancer.

Authors:  Tara Gangadhar; Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2010-05-04       Impact factor: 66.675

2.  Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Authors:  David S Williams; Dmitri Mouradov; Clare Browne; Michelle Palmieri; Meg J Elliott; Rebecca Nightingale; Catherine G Fang; Rita Li; John M Mariadason; Ian Faragher; Ian T Jones; Leonid Churilov; Niall C Tebbutt; Peter Gibbs; Oliver M Sieber
Journal:  Mod Pathol       Date:  2019-08-30       Impact factor: 7.842

Review 3.  Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.

Authors:  B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor
Journal:  Int J Colorectal Dis       Date:  2003-06-21       Impact factor: 2.571

4.  p53 protein expression affected by TP53 polymorphism is associated with the biological behavior and prognosis of low rectal cancer.

Authors:  Guangzhe Zhang; Qian Xu; Zeyang Wang; Liping Sun; Zhi Lv; Jingwei Liu; Chengzhong Xing; Yuan Yuan
Journal:  Oncol Lett       Date:  2019-10-18       Impact factor: 2.967

5.  p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer?

Authors:  D N Poller; K J Baxter; N A Shepherd
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Stromal tenascin distribution as a prognostic marker in colorectal cancer.

Authors:  U Kressner; G Lindmark; B Tomasini-Johansson; R Bergström; B Gerdin; L Påhlman; B Glimelius
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Growth dysregulation and p53 accumulation in human primary colorectal cancer.

Authors:  D S Watson; I Brotherick; B K Shenton; R G Wilson; F C Campbell
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

8.  Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer.

Authors:  U Kressner; B Glimelius; R Bergström; L Påhlman; A Larsson; G Lindmark
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

9.  Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas.

Authors:  D R Smith; C Y Ji; H S Goh
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

10.  Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma.

Authors:  R J Slebos; I O Baas; M Clement; M Polak; J W Mulder; F M van den Berg; S R Hamilton; G J Offerhaus
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.